Post hoc analyses of some Phase 3 placebo-controlled studies showed that adding Spiriva Respimat improved peak FEV1(0-3h) and trough FEV1 across a range of baseline IgE levels and eosinophil counts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback